Plasmodium berghei ANKA was tested for its usefulness as a model for cerebral malaria in inbred mouse strains A, A2G, A/J, C57L, SJL/J and SWR. A suitable model was obtained in A or A/J strain mice. Mortality was 100% after five to eight days with brain haemorrhages occurring terminally. The histopathology is described. The model was stable after six blood passages at 5- to 7-day intervals. Chloroquine abolished the haemorrhages and no intercurrent viral or blood protozoal infections were detected.

Résumé— La dermatose lupoïde du Braque Allemand doit être considéré comme une génodermatose bien que le nombre de cas décrit soit faible. Cette maladie concerne de jeunes chiens. Aucune prédisposition sexuelle n'est notée. Pour l'instant, cette maladie n'a été observée que chez le Pointer. Le diagnostic repose sur l'examen clinique et l'examen histopathologique des biopsies cutanées. Le pronostic est généralement réservé, mais l'utilisation des acides gras et un traitement symptomatique peuvent être préconisés. [Vroom, M.W., Theaker, M.J., Rest, J.R., White, S.D. Lupoid dermatosis in five German short‐haired pointers (Dermatose lupoïde chez cinq Braques Allemands). Resumen— La dermatosis lupoide del Pointer Alemán de pelo corto podria ser un genodermatosis, aunque el número de casos descritos es bajo. Esta enfermedad se presenta en perros jóvenes. No hay predisposición por sexo. Hasta el momento sólo se ha descrito como tal en el Pointer Alemán de pelo corto. El diagnóstico se realiza mediante examen clinico e histopatológico de biopsias cutáneas. El pronóstico es grave, pero se recomienda un tratamiento sintomático y con ácidos grasos. [Vroom, M.W., Theaker, M.J., Rest, J.R., White, S.D. Lupoid dermatosis in five German short‐haired pointers (Dermatosis lupoide en cinco perros Pointer alemán de pelo corto). Abstract— Lupoid dermatosis of the German short‐haired pointer may be a genodermatosis, although the number of cases reported is low. The disease occurs in young dogs. There is no sex predisposition. Until now the disease has only been consistently described in the German short‐haired pointer. Diagnosis can be made by clinical examination together with histopathological examination of skin biopsies. The prognosis is usually poor, but fatty acid and symptomatic treatment should be attempted.

No abstract

A randomized, double-blind, placebo-controlled, parallel-group clinical trial was carried out to compare 24-week periods of treatment with 1 g acetyl-l-carnitine twice daily and placebo in the treatment of patients with dementia of the Alzheimer type. A total of 36 patients entered the trial, of whom 20 patients (7 active, 13 placebo) completed the full 24 weeks. Whilst several of the efficacy indices showed little change in either group during the trial, there was an apparent trend for more improvement in the acetyl-l-carnitine group in relation to the Names Learning Test and a computerized Digit Recall Test, both related to aspects of short-term memory. Similarly, there was a trend for reaction time in the computerized classification test to show less deterioration in the active treatment group. Changes within groups, and changes between groups, failed to reach statistical significance, at least partially because of the small number of patients available for analysis. Two indices of overall therapeutic benefit showed a trend for less deterioration in the active-treatment group than in the placebo group. Nausea and/or vomiting occurred in 5 patients in the acetyl-l-carnitine group. Laboratory tests revealed no signs of drug toxicity. The results suggest that acetyl-l-carnitine may have a beneficial effect on some clinical features of Alzheimer-type dementia, particularly those related to short-term memory.

No abstract